Patient Guide: A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 58 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06500702
Status: 🟢 Enrolling Now
Condition: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Phase: PHASE2

Where You Can Participate

This study is available at 58 locations across the country.

Top locations include:
  • • Birmingham, Alabama
  • • Orange, California
  • • San Francisco, California
  • • And 55 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease - Join Clinical Trial NCTNCT06500702

How to Join This Clinical Trial - NCTNCT06500702

Learn how to participate in this PHASE2 trial studying an investigational therapy for Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06500702 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 58 locations. Find a study site near you:

Clinical Research Site

Birmingham, Alabama 35233 - United States

Status: RECRUITING

Clinical Research Site

Orange, California 92868 - United States

Status: RECRUITING

Clinical Research Site

San Francisco, California 94143 - United States

Status: RECRUITING

Clinical Research Site

Chicago, Illinois 60611 - United States

Status: RECRUITING

Clinical Research Site

Hinsdale, Illinois 60521 - United States

Status: RECRUITING

Clinical Research Site

Ann Arbor, Michigan 48109 - United States

Status: RECRUITING

Clinical Research Site

Edina, Minnesota 55435 - United States

Status: RECRUITING

Clinical Research Site

Las Vegas, Nevada 89107 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10032 - United States

Status: RECRUITING

Clinical Research Site

Chapel Hill, North Carolina 27599 - United States

Status: RECRUITING

And 48 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships